본문으로 건너뛰기
← 뒤로

[Chinese expert consensus on the clinical application of next-generation sequencing technology in myelodysplastic neoplasms (2026)].

1/5 보강
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 📖 저널 OA 74.3% 2025: 15/15 OA 2026: 11/20 OA 2025~2026 2026 Vol.47(1) p. 6-13
Retraction 확인
출처
📝 환자 설명용 한 줄

Myelodysplastic neoplasms (MDS) are a group of highly heterogeneous myeloid malignancies characterized by cytopenia, dysplasia, and a high risk of leukemic transformation.

이 논문을 인용하기

↓ .bib ↓ .ris
APA (2026). [Chinese expert consensus on the clinical application of next-generation sequencing technology in myelodysplastic neoplasms (2026)].. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 47(1), 6-13. https://doi.org/10.3760/cma.j.cn121090-20251106-00511
MLA . "[Chinese expert consensus on the clinical application of next-generation sequencing technology in myelodysplastic neoplasms (2026)].." Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, vol. 47, no. 1, 2026, pp. 6-13.
PMID 41663178 ↗

Abstract

Myelodysplastic neoplasms (MDS) are a group of highly heterogeneous myeloid malignancies characterized by cytopenia, dysplasia, and a high risk of leukemic transformation. Next-generation sequencing (NGS) technology enables efficient detection of gene mutations and has been incorporated into the diagnostic classification, prognostic assessment, and treatment decision-making systems for MDS. To further standardize the clinical application of NGS technology in MDS, Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association have developed this expert consensus by integrating the latest advances in MDS diagnosis and treatment, relevant domestic and international guidelines/consensus recommendations, and expert opinions from China. The aim is to promote the rational use of NGS in the diagnosis and treatment of MDS in China.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반